and hemolytic anemia. 1, 2, 4 Of the autoantibodies associated with APS, lupus anticoagulant is the strongest predictor of thrombotic complications related to the disorder. 2, 4, 5 Diagnosis of APS is confirmed by having a documented clinical episode (vascular thrombosis or pregnancy morbidity) and at least one positive antibody laboratory test. The antibody laboratory test must be positive on 2 or more occasions, at least 12 weeks apart. 4, 6 Plasma antibodies associated with APS are lupus anticoagulant, anticardiolipin, and anti-beta Volume 51, October 2016 2-glycoprotein I. Coagulation assays are used to identify lupus anticoagulant antibodies, because they are associated with a prolonged clotting time. In contrast, immunoassays are used to measure immunologic reactivity to phospholipids to determine the presence of anticardiolipin and anti-beta2-glycoprotein I antibodies. 7, 8 Guidelines for detection of lupus anticoagulant stress the importance of proper patient selection for testing in order to avoid false-positive results. 9 Testing for lupus anticoagulant in asymptomatic patients is highly discouraged. 10 In patients with recurrence of VTE on anticoagulation therapy with either a novel oral anticoagulant (NOAC) or vitamin K antagonist (VKA), the 2016 guidelines from the American College of Chest Physicians recommend 1 month of low-molecular-weight heparin along with an evaluation for adherence and malignancy. However, the guidelines note that this recommendation is based on low-quality evidence and assessment of probable cause of reoccurrence. After a 1-month period, patients should restart their oral anticoagulation therapy unless cancer was identified. In addition, the guidelines recommend choosing anticoagulation therapy based on patient-specific factors such as renal or liver disease, coronary artery disease, adherence, and patient preference. The 2016 guidelines mention APS as a risk factor associated with recurrent VTE, although specific treatment is not outlined. 11 Prior to the new guidelines, the standard treatment for APS with history of thromboembolism was long-term therapy with a VKA such as warfarin to target an international normalized ratio (INR) of 2.5 (range, 2.0-3.0). 12 In APS patients who have had recurrent thromboembolic events and arterial thrombosis, a target INR of 3.0 (2.5-3.5) was suggested. 5 However, this is controversial. Two studies have shown high-intensity warfarin therapy (INR 3.1-4.0) was not superior to moderate-intensity warfarin therapy (INR 2-3) in the prevention of thrombosis in patients with APS. 13, 14 Therefore, moderate-intensity warfarin (INR 2-3) therapy is preferred for patients with APS compared to high-intensity warfarin in the prevention of recurrent thrombosis. 12 Treatment of APS with a VKA presents a challenge in monitoring and adjustment, and it can be complicated by lupus anticoagulant interference on INR results. Lupus anticoagulant interference can lead to variability and misinterpretation of the INR, which can result in under-dosing of the VKA and VTE recurrence. 15, 11 VKAs also have several drugdrug and drug-food interactions that require dietary restrictions and frequent laboratory monitoring to achieve a therapeutic INR. 5 Despite treatment with VKAs, thrombosis still occurs in 5% to 20% of APS patients; therefore, complete protection against all future thrombotic events is highly improbable in some APS patients. 13, 16 Several new APS treatment approaches are emerging, including combination antiplatelet therapies (low-dose aspirin plus clopidogrel or dipyridamole), oral anti-factor Xa medications (rivaroxaban, apixaban), direct thrombin inhibitors (dabigatran), statins (fluvastatin, rosuvastatin), hydroxychloroquine, and B-cell depletion therapy (rituximab). 16 In theory, the NOACs should be effective in patients with APS. Several NOACs (rivaroxaban, dabigatran, edoxaban, and apixaban) are on the market, but none carry indications for treatment related to APS or other hypercoagulable disorders. The NOACs are more attractive because of the need for less routine laboratory monitoring, fewer diet restrictions, decreased drug interactions, and a once-to twicedaily dosing strategy. In addition, they have predictable anticoagulant effects, yet these agents are at a disadvantage because of limited reversal possibilities and the possibility of patient-specific dosage adjustments. 5, 15 An overview of the NOACs is outlined in Table 1 . [17] [18] [19] [20] [21] [22] Currently, dabigatran, rivaroxaban, and apixaban have published literature related to treatment in APS and are the focus of this article.
CLINICAL EVIDENCE Case Studies
Several case reports have been published regarding the use of NOACs in APS ( Table 2) . Five of the case reports reference rivaroxaban, whereas 2 include patients on dabigatran. Signorelli et al reported 8 patients (mean age of 36 years and 62.5% female) who suffered a thrombotic event while on NOAC therapy. Of those 8 patients, 3 had a thrombotic event on warfarin therapy prior to switching to rivaroxaban, and 5 had a reported target INR range of 3 to 4. In addition, one patient was identified as nonadherent to medication regimens including warfarin and rivaroxaban. 23 Win and Rodgers reported 3 patients with a thrombotic event on NOAC therapy within 6 to 12 months after switching from warfarin therapy. All these patients had either failed warfarin therapy or had difficulty maintaining a therapeutic INR due to nonadherence or genetic predisposition related to cytochrome P450 (CYP) 2C9. Two patients were switched to rivaroxaban, and one patient received a reduced dose of dabigatran (150 mg daily). All 3 patients reported a thrombotic event while receiving NOAC therapy. All patients improved after switching to either enoxaparin (n = 2) or fondaparinux (n = 1). 24 Schaefer et al described 3 patients who experienced a thrombotic event while on NOAC. Two patients reported bleeding complications with warfarin, one of whom had a target INR of 3 to 4 prior to switching to a NOAC. The third patient switched to rivaroxaban due to patient preference related to frequent INR monitoring with warfarin. One patient was switched to lower dabigatran dose (150 mg once daily) based on moderate renal impairment, and others were dosed with rivaroxaban 20 mg daily due to patient preference. All patients experienced another thrombotic event on an NOAC. Two patients were transitioned to warfarin and one to enoxaparin. 25 Son et al followed 12 patients at one institution who were switched from a VKA to rivaroxaban due to logistical issues with the patients' professional activities in conjunction with frequent laboratory monitoring or unstable INR values. Patients ranged from 22 to 52 years of age, and 58% were female. Patients with a history of stroke and/or multiple risk factors for thrombotic events also received low-dose aspirin. Of the 12 patients, only 2 experienced a thrombotic event on rivaroxaban over a treatment range of 10 to 16 months. One patient had a deep vein thrombosis (DVT) during an exacerbation of systemic lupus erythematosus (SLE), and the other developed a DVT after a minor lower limb injury. Both of these patients had a coexisting SLE and triple positivity profile. 26 Savino et al tracked 35 patients who were either started on rivaroxaban prior to the clinical trial of rivaroxaban in APS (RAPS) or failed to qualify for the enrollment in the trial. Patients were excluded if they had arterial thrombosis. The patients ranged from 17 to 75 years of age, and the majority were female (24 woman; 11 men). The patients either had a previous DVT, pulmonary embolism (PE), or both. All were previously treated with warfarin with a target INR of 2 to 3. Patients were followed for a median of 10 months (6-24 months) and were treated with rivaroxaban of 20 mg once daily. During that time frame, no patient suffered a recurrent thrombotic event. Two patients reported increased menorrhagia. 27
Observational Cohort Study
Noel et al conducted a multicenter observational study that followed 26 APS patients treated with either dabigatran (n = 11; 150 mg twice daily) or rivaroxaban (n = 13; 20 mg once daily). Two patients received a different dose of rivaroxaban (n = 1, 15 mg twice daily; n = 1, 15 mg daily). Twelve patients had primary APS, 9 had APS associated with SLE, and 5 had APS associated with various other syndromes. Twenty-two patients had normal renal function, and 4 patients had moderate kidney impairment (glomerular filtration rate 40-60 mL/min/1.73 m 2 ). Twenty patients had previous anticoagulation therapy (warfarin, n = 19; fondaparinux, n = 1). Two patients were switched from warfarin therapy: one patient had a recurrent venous thrombosis and the other had a bleeding event. Sixteen patients were switched to the NOAC due to labile INRs. One patient experienced a recurrent thrombotic event after 8 months of rivaroxaban. The event-free survival rate was 87.9% at 12 months and 82.4% at 24 months. Three patients withdrew from the rivaroxaban group due to adverse events (n = 2, bleeding events; n = 1, recurrent migraines). 28
Controlled, Clinical Trials
Three controlled, clinical trials are currently underway that evaluate NOACs compared to warfarin with an adjusted INR of 2 to 3 (target 2.5) in APS. An overview of the studies is outlined in Table 3 .
Rivaroxaban in antiphospholipid syndrome (RAPS) clinical trial is designed to evaluate the level of anticoagulation compared to warfarin in the APS population with or without SLE and a history of VTE. The secondary endpoints focus more on efficacy and safety. Patients with arterial thrombosis, severe renal impairment, history of nonadherence, or a thrombotic event while on warfarin with a therapeutic INR (2-3) were excluded from the trial. 29 The Trial on Rivaroxaban in Thrombotic Antiphospholipid Syndrome (TRAPS) is designed to determine noninferiority of rivaroxaban compared to warfarin in the prevention of acute thrombosis in patients with triple antiphospholipid antibody positive APS and bleeding risk. Currently in the recruitment phase, this multicenter trial will include patients with arterial thrombosis and moderate renal impairment (creatinine clearance [CrCL] 30-50 mL/min). The moderate renal impairment group will be dosed with rivaroxaban 15 mg once daily based on the recommendation by the American College of Cardiology/American Heart Association Task Force related to dosing in the trials associated with nonvalvular atrial fibrillation. 22, 30 A feasibility pilot study is currently in progress with Apixaban for Secondary Prevention of Thrombosis among Patients with APS (ASTRO-APS). Patients will be enrolled from 2 health care systems comprising more than 160 outpatient clinics and Volume 51, October 2016 Table 3 . Protocol summary of the clinical control trials for treatment of APS with new oral anticoagulants [29] [30] [31] Trial 
DISCUSSION
The use of NOACs in the treatment of APS remains controversial, yet new data from emerging clinical trials may shed light on the utility of these new agents compared to the current standard of care with warfarin. There are no completed studies that evaluate the use of NOACs compared to VKAs in APS, yet approximately 10% of patients with acute VTE have APS. Some patients with APS were likely included in previous clinical trials with the NOACs. 32, 33 A small subset of patients with thrombophilic disorders (5%-7%) was included in the EIN-STEIN and EINSTEIN-PE trials with rivaroxaban, but no specific information was recorded to identify the type of hypercoagulable disorder. 34, 35 In the case reports discussed above, thrombotic events seemed to occur most often in the higher risk population or in patients who had previously failed warfarin therapy. The studies by Son, Savino, and Noel, which demonstrated low event rates, included patients reflective of the general APS population. [26] [27] [28] Methodology of the TRAPS clinical trial will target a higher risk population and should therefore provide more meaningful guidance on appropriate therapy across the APS spectrum. 30 The literature shows that there is an increased risk of thrombotic events associated with a history of arterial occlusions and/or triple antibody positivity APS regardless of treatment with warfarin or the NOACs. In previous trials related to DVT and atrial fibrillation, NOACs were compared to warfarin with a target INR 2 to 3. With arterial thrombosis, it is controversial whether a higher target INR range of 3 to 4 is beneficial in reducing the risk of thrombotic events in APS, yet the INR target is set at 2.5 in all 3 ongoing trials evaluating use of NOACs in APS. Therefore, equivalent dosing of NOACs for an adjusted INR of 3 to 4 is unknown. Patients with a history of arterial thrombosis and APS may be underdosed with current dosing guidelines. However, APS patients with previous DVT or PE event remained event-free for a median of 10 months while being treated with an NOAC. 27 This is promising data, which hopefully will be confirmed with new controlled clinical trials.
When evaluating patients for APS, it is important to consider the impact of the anticoagulant on accuracy of diagnostic laboratory assays. Warfarin and heparin products have the potential to affect the results of many of the hypercoagulable panels. Thrombophilia testing is also vulnerable to interference by the NOACs. When the NOACs are given prior to testing, prolonged clotting times can cause false-positive results for protein C & S and for lupus anticoagulant in assays done with activated partial thromboplastin time (aPTT) and dilute Russell's viper venom time (dRVTT). 36 However, taipan/ecarin time is less affected by the presence of rivaroxaban and may provide the best specificity and positive predictive value in testing for APS while using rivaroxaban. 23, 27 NOACs can also affect whole blood clotting tests (eg, dabigatran prolongs activated clotting time). 37 Therefore, testing prior to the administration of anticoagulants or at least 4 to 6 weeks after discontinuation of therapy is recommended. 38 One major disadvantage of the NOACs is the limited availability of reversal agents for patients with a major bleeding event. 4, 5 In the case and observational studies, minor bleeding was reported with NOACs that required discontinuation of therapy. 27.28 Currently, Praxbind (idaricizumab; Boehringer Ingelheim) is available for reversal of dabigatran, but no antidotes are available at this time for the oral Factor Xa inhibitors. Management of bleeding when using the NOACs includes supportive care with blood products and fluids as needed; use of gastric lavage, activated charcoal, or hemodialysis with dabigatran; or possibly use of activated prothrombin complex concentrate (FEIBA NF). 39 The 14th International Congress of Antiphospholipid Antibodies Task Force published a report on the current treatment trends related to APS in 2014, which recommended VKAs as the treatment option for APS patients with thrombotic events. 16 However, NOACs may be considered in patients with thrombotic events on subtherapeutic anticoagulation or intolerance to VKAs. 16 These recommendations were published prior to the availability of the clinical evidence presented in this article. Therefore, the clinical evidence sheds light on the possibility of NOACs for the general APS population. Emerging data from new clinical trials will need to be analyzed to formulate a more contemporary recommendation.
